Control of cell proliferation and differentiation in breast and prostate cancer

控制乳腺癌和前列腺癌的细胞增殖和分化

• 批准号: nhmrc : 276408
• 负责人: Prof Christopher Ormandy
• 金额: $ 336.27万
• 依托单位: Garvan Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Programs
• 财政年份: 2003
• 资助国家: 澳大利亚
• 起止时间: 2003-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/control-cell-proliferation-prostate-cancer/81665
• 关键词: Control; cell; proliferation; differentiation; breast

Breast and prostate cancer are the most commonly diagnosed cancers in women and men respectively, together accounting for >25% of all newly diagnosed cancers in Australia and other developed countries. Although significant improvements in the management of these cancers have occurred in the past 20 years further research is needed to better understand the molecular mechanisms of disease development and progression. Such research is critical to the better management and ultimate control of these diseases through better treatments and prevention. A multidisciplinary team of cancer researchers at the Garvan Institute of Medical Research, with a 10 year track record of discovery and application of their research into breast and prostate cancer, will employ state-of-the-art research tools to identify new molecules and molecular pathways involved in these diseases. This new information will facilitate the improved management of these cancers through improved assessment of disease progression at the time of diagnosis and the development of new drugs and strategies for treatment and prevention.

乳腺癌和前列腺癌分别是女性和男性最常见的癌症，占澳大利亚和其他发达国家所有新诊断癌症的25%。尽管在过去的20年里，这些癌症的管理有了显着的改善，但仍需要进一步的研究来更好地了解疾病发展和进展的分子机制。这种研究对于通过更好的治疗和预防来更好地管理和最终控制这些疾病至关重要。Garvan医学研究所的一个多学科癌症研究人员团队，在乳腺癌和前列腺癌研究中有10年的发现和应用记录，将采用最先进的研究工具来识别这些疾病中涉及的新分子和分子途径。这些新信息将有助于通过在诊断时改善对疾病进展的评估以及开发新的治疗和预防药物和策略来改善对这些癌症的管理。